OncoMatch

OncoMatch/Clinical Trials/NCT05702229

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Is NCT05702229 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for gastric cancer.

Phase 2RecruitingAstraZenecaNCT05702229Data as of May 2026

Treatment: Rilvegostomig · Volrustomig · FOLFOX · XELOX · AZD0901 · 5-Fluorouracil · Capecitabine — This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Gastric Cancer

Biomarker criteria

Required: CLDN18 central lab confirmed Claudin18.2 status

Has central lab confirmed Claudin18.2 status at screening from archival tumour collected within past 24 months or from a fresh biopsy when Substudy 3, Substudy 4 is open for recruitment.

Required: HER2 (ERBB2) overexpression (3+ by IHC, or 2+ by IHC and positive by in situ hybridisation)

Participants with HER2-positive (3+ by IHC, or 2+ by IHC and positive by in situhybridisation) or indeterminate gastric or GEJ carcinoma [excluded]

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: immune-oncology agent

Previous treatment with an immune-oncology agent.

Cannot have received: Claudin18.2 targeted therapy

Previous treatment with any modalities of Claudin18.2 target therapy or MMAE exposure (when Substudy 3, Substudy 4 is open for recruitment).

Cannot have received: MMAE-containing therapy

Previous treatment with any modalities of Claudin18.2 target therapy or MMAE exposure (when Substudy 3, Substudy 4 is open for recruitment).

Lab requirements

Blood counts

adequate organ and bone marrow function

Kidney function

Liver function

Adequate organ and bone marrow function.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Research Site · Los Angeles, California
  • Research Site · Los Angeles, California
  • Research Site · Baton Rouge, Louisiana
  • Research Site · Grand Rapids, Michigan
  • Research Site · New Hyde Park, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify